Patents by Inventor Andrew Milstead

Andrew Milstead has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Lipids and compositions thereof
    Patent number: 12263228
    Abstract: Provided herein are lipids having the Formula I or Formula Ia: and pharmaceutically acceptable salts thereof, wherein R?, R1, R2, R3, R4, R5, R6a, R6b, X1, X2, and n are as defined herein for Formula I and Formula Ia, respectively. Also provided herein are lipid nanoparticle (LNP) compositions comprising lipid having the Formula I or Ia and a capsid-free, non-viral vector (e.g., ceDNA). In one aspect of any of the aspects or embodiments herein, these LNPs can be used to deliver a capsid-free, non-viral DNA vector to a target site of interest (e.g., cell, tissue, organ, and the like).
    Type: Grant
    Filed: March 21, 2024
    Date of Patent: April 1, 2025
    Assignee: Generation Bio Co.
    Inventors: Matthew G. Stanton, Birte Nolting, Andrew Milstead
  • CATIONIC LIPIDS AND COMPOSITIONS THEREOF
    Publication number: 20240293574
    Abstract: Provided herein are cationic lipids having the Formula I or la: and pharmaceutically acceptable salts thereof, wherein R?, R1, R2, R3, R4, R5, R6a, R6b, X, and n are as defined herein. Also provided herein are lipid nanoparticle (LNP) compositions comprising a cationic lipid having the Formula I or la and a capsid-free, non-viral vector (e.g., ceDNA). In one aspect of any of the aspects or embodiments herein, these LNPs can be used to deliver a capsid-free, non-viral DNA vector to a target site of interest (e.g., cell, tissue, organ, and the like).
    Type: Application
    Filed: June 14, 2022
    Publication date: September 5, 2024
    Inventors: Matthew G. Stanton, Birte Nolting, Andrew Milstead
  • CATIONIC LIPIDS AND COMPOSITIONS THEREOF
    Publication number: 20240285796
    Abstract: Provided herein are lipids having the Formula I or Formula Ia: and pharmaceutically acceptable salts thereof, wherein R?, R1, R2, R3, R4, R5, R6a, R6b, X1, X2, and n are as defined herein for Formula I and Formula Ia, respectively. Also provided herein are lipid nanoparticle (LNP) compositions comprising lipid having the Formula I or Ia and a capsid-free, non-viral vector (e.g., ceDNA). In one aspect of any of the aspects or embodiments herein, these LNPs can be used to deliver a capsid-free, non-viral DNA vector to a target site of interest (e.g., cell, tissue, organ, and the like).
    Type: Application
    Filed: March 21, 2024
    Publication date: August 29, 2024
    Inventors: Matthew G. Stanton, Birte Nolting, Andrew Milstead
  • CATIONIC LIPIDS AND COMPOSITIONS THEREOF
    Publication number: 20240226325
    Abstract: Provided herein are lipids having the Formula I or Formula la, and pharmaceutically acceptable salts thereof, wherein R?, R1, R2, R3, R4, R5, R6a, R6b, X1, X2, and n are as defined herein for Formula I and Formula la, respectively. Also provided herein are lipid nanoparticle (LNP) compositions comprising lipid having the Formula I or la and a capsid-free, non-viral vector (e.g., ceDNA). In one aspect of any of the aspects or embodiments herein, these LNPs can be used to deliver a capsid-free, non-viral DNA vector to a target site of interest (e.g., cell, tissue, organ, and the like).
    Type: Application
    Filed: April 20, 2022
    Publication date: July 11, 2024
    Inventors: Matthew G. Stanton, Birte Nolting, Andrew Milstead